EIF2AK3 and colorectal cancer: Again, in colorectal cancer, the pharmacological PERK activator CCT020312 was found to strongly enhance the cytotoxic action of treatment with the antimitotic agent paclitaxel (taxol), both in vitro and in vivo [164].